Oral Session 2-14A GVHD: Clinic

[OS2-14A-4] A prognostic impact of complete or partial response at 1 year after onset in 2005 NIH chronic GVHD

Chikako Ohwada¹, Emiko Sakaida¹, Aiko Igarashi², Noriko Doki², Takehiko Mori³, Jun Kato³, Heiwa Kanamori⁴, Masatsugu Tanaka⁴, Shin Fujisawa⁵, Eriko Ogusa⁵, Masako Toyosaki⁶, Yasuyuki Aoyama⁶, Yoshinobu Kanda⁷, Hideki Nakasone⁷, Maki Hagihara⁸, Hiroaki Shimizu⁹, Seiko Kato¹⁰, Reiko Watanabe¹¹, Katsuhiro Shono¹², Rika Sakai¹³, Takeshi Saito¹⁴, Kensuke Usuki¹⁵, Chiaki Nakaseko¹⁶, Shinichiro Okamoto^3,17 (1.Department of Hematology, Chiba University Hospital, 2.Hematology Division, Tokyo Metropolitan Cancer, 3.Division of Hematology, Keio University School of Medicine, 4.Department of Hematology, Kanagawa Cancer Center, 5.Department of Hematology, Yokohama City University Medical Center, 6.Division of Hematology/Oncology, Tokai University School of Medicine, 7.Division of Hematology, Saitama Medical Center, Jichi Medical University, 8.Department of Hematology and Clinical Immunology, Yokohama City University, 9.Department of Hematology, Gunma University School of Medicine, 10.Department of Hematology, The Institute of Medical Science, Tokyo University, 11.Department of Hematology, Saitama Medical Center, Saitama Medical University, 12.Division of Hematology, Chiba Aoba Municipal Hospital, 13.Kanagawa Cancer Center Department of Medical Oncology, 14.Division of Clinical Oncology/Hematology, Jikei University, 15.Division of Hematology, NTT Medical Center Tokyo, 16.Department of Hematology, International University of Health and Welfare, 17.Kanto Study Group for Cell Therapy (KSGCT))